Research & Reviews: Journal of Medical and Health Sciences

e-ISSN: 2319-9865
p-ISSN: 2322-0104

Role of Immunoglobulin against Infections

Md Shabana Sultana*

Department of Biotechnology, Andhra University, Vishakhapatnam, Andhra Pradesh, India

Review Article

Received: 28-07-2016
Accepted: 29-07-2016
Published: 02-08-2016
***For Correspondence**

Shabana S Md, Department of Biotechnology, Andhra University, Vishakhapatnam, Andhra Pradesh, India, Tel: 7382749069.

Keywords: Immunoglobulin related cancer diseases, Antibody, Variable region

E-mail:
shabanasultana2@gmail.com

ABSTRACT

Immunoglobulin is nothing but an antibody that is produced by the white blood cells present in our body. It is very useful in the critical situation of immune response.

Antibodies are substances made by the body's immune system because of microorganisms, infections, growth, or cancer cells. Antibodies join to the foreign substances so the immune system will against them.

Antibodies are particular to every kind of foreign substance. For example, antibodies made because of a tuberculosis contamination connect only to tuberculosis microorganisms. Antibodies also work in allergic responses. Sometimes, antibodies might be made against your own particular tissues. This is called an autoimmune disease.

INTRODUCTION

Killer cell immunoglobulin receptor contains the qualities that encode for enacting and inhibitory surface receptors, which are related with the control of Natural Killer cell cytotoxic action [1]. Diminished natural killer cell cytotoxic movement has been reliably reported in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients, and killer cell immunoglobulin haplotypes and allelic polymorphism stay to be explored. The point of this article was to direct a pilot study to analyze Killer cell immunoglobulin genotypes, haplotypes, and allelic polymorphism in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients and nonfatigued controls [2]. Examination of Killer cell immunoglobulin and allelic polymorphism frequencies uncovered no huge contrasts between 20 chronic fatigue syndrome/ myalgic patients and 20 non fatigued controls. Further studies with a bigger Chronic Fatigue Syndrome/Myalgic Encephalomyelitis associate are required to accept these outcomes. cell immunoglobulin-like receptor qualities encode for enacting and inhibitory surface receptors, which are related with the control of Natural Killer cell cytotoxic action [3,4]. Diminished Natural Killer cell cytotoxic movement has been reliably reported in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients, and killer cell immunoglobulin haplotypes and allelic polymorphism stay to be explored. The point of this article was to direct a pilot study to analyze killer cell immunoglobulin genotypes, haplotypes, and allelic polymorphism in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients and nonfatigued controls [5,6]. Examination of Killer cell immunoglobulin and

e-ISSN: 2319-9865
p-ISSN: 2322-0104

allelic polymorphism frequencies uncovered no huge contrasts between 20 Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients and 20 nonfatigued controls.

Prostate cancer is the second most basic type of tumor in men around the world. Biomarkers have developed as fundamental devices for treatment and appraisal since the variability of disease conduct, the expense and diversity qualities of medications, and the related impairment of personal satisfaction have offered ascend to a requirement for a customized approach [7,8]. High-throughput innovation stages in proteomics and genomics have quickened the advancement of biomarkers [9]. Moreover, late achievements of a few new operators in Prostate cancer, including immunotherapy, have fortified the quest for indicators of reaction and resistance and have enhanced the comprehension of the organic systems at work [10,11]. This survey gives a diagram of right now settled biomarkers in Prostate cancer, and also a determination of the most encouraging biomarkers inside these specific fields of advancement [12,13].

Immune system regulations usually reveal synergistic modulation with other cancer mechanisms and in combination provide insights on possible advances in cancer immunotherapies. Network inference is a powerful approach to decipher pan-cancer systems dynamics [14,15]. The methodology proposed in this study elucidates the impacts of epigenetic treatment on the drivers of complex pan-cancer regulation circuits involving cell lines of five cancer types. These patterns were observed from differential gene expression measurements following demethylation with 5-azacytidine [16,17]. Networks were built to establish associations of phenotypes at molecular level with cancer hallmarks through both transcriptional and post-transcriptional regulation mechanisms [18-20]. The most prominent feature that emerges from our integrative network maps, linking pathway landscapes to disease and drug-target associations, refers primarily to a mosaic of immune-system crosslinked influences. Therefore, characteristics initially evidenced in single cancer maps become motifs well summarized by network cores and fingerprints [21,22].

Immune system controls for the most part uncover synergistic adjustment with other disease instruments and in mix give bits of knowledge on conceivable advances in growth immunotherapies [23,24]. The approach proposed in this study explains the effects of epigenetic treatment on the drivers of complex skillet disease direction circuits including cell lines of five growth sorts [25-27]. These examples were seen from differential quality expression estimations taking after demethylation with 5-azacytidine. Systems were worked to set up relationship of phenotypes at atomic level with growth trademarks through both transcriptional and post-transcriptional direction instruments [28-30]. The most unmistakable element that rises up out of our integrative system maps, connecting pathway scenes to ailment and medication target affiliations, alludes principally to a mosaic of resistant framework cross-linked impacts. In this way, qualities at first confirm in single tumor maps get to be themes very much condensed by system centres and fingerprints [31,32].

e-ISSN: 2319-9865
p-ISSN: 2322-0104

Triple negative breast cancer is an exceedingly heterogeneous tumor. There is expanding confirmation of the part of tumor lymphocytic insusceptible invades in this subtype of bosom disease [33-35]. Hearty levels of tumor invading lymphocytes have been connected with enhanced illness free and general survival rates in triple negative breast cancer patients with and with no treatment [36,37]. Late endeavors have been made to build up an institutionalized approach for assessing tumor lymphocytes [38]. The nearness of TILs in the bosom tumor microenvironment can likewise foresee reactions to neoadjuvant as well as to adjuvant chemotherapy medications [39,40]. High quantities of tumor invading lymphocytes connect with expanded neurotic complete reactions in triple negative breast cancer [41,42]. Tumor invading lymphocytes are prognostic and prescient of reaction to standard treatments [43]; hence, the insusceptible framework seems to assume a dynamic part in a subgroup of bosom disease [44,45]. There is an expanding enthusiasm for specifically focusing on the insusceptible framework as a major aspect of bosom disease treatment, mostly in patients with triple negative breast cancer [46,47]. New insusceptible modulatory specialists, including safe checkpoints inhibitors, have indicated promising action in a subgroup of metastatic triple negative breast cancer [48-50]. The modified cell passing protein inhibitor pembrolizumab, and the inhibitor atezolizumab have indicated promising results in clinical trials.

REFERENCES

1. Malemud CJ, et al. Matrix metalloproteinase-9 production by immortalized human chondrocyte lines. J Clin Cell Immunol. 2016;7:422.
2. Lopes DN, et al. Multi insulin sensitization with tolerante to new therapeutic option: degludec. J Diabetes Metab. 2016;7:668.
3. Jena PK, et al. Influence of gut microbiota on inflammation and pathogenesis of sugar rich diet induced diabetes. Immunome Res. 2016;12:109.
4. Caprio MG, et al. Vascular disease in patients with multiple sclerosis: a review. J Vasc Med Surg. 2016;4:259.
5. Rance E, et al. A method for in situ localization of single-strand and double-strand rna elements contained in the hepatitis c virus genome 3'-untranslated region. Adv Tech Biol Med. 2016;4:171.
6. Behice K. Antiviral treatment of flu: is a vicious circle? health care: Current Reviews. 2016;4:158.
7. Luisa WM, et al. Culture-independent analysis of bacterial diversity during bioremediation of soil contaminated with a diesel-biodiesel blend (b10)s. J Bioremed Biodeg. 2015;6:318.
8. Priyanka MJ and Nilima AK. Innovative approach for classification of traditional system of medicine. Nat Prod Chem Res. 2015;3:191.
9. Kandaswamy R. Autism: new understanding of the symptoms through discoveries made in psychoneuroimmunology. Autism Open Access. 2015;5:e134.
10. Niederkorn JY. Immunology of corneal allografts: insights from animal models. J Clin Exp Ophthalmol. 2015;6:429.

e-ISSN: 2319-9865
p-ISSN: 2322-0104

11. Patella V, et al. A cough of unknown origin: an often serious, unmet clinical problem. J Allergy Ther. 2015;6:210.
12. Tröger V, et al. Isothermal amplification and quantification of nucleic acids and its use in microsystems. J Nanomed Nanotechnol. 2015;6: 282.
13. Tecu C and Ungureanu V. Is it possible that an acute demyelinating encephalitis at an adult 38 years old to be caused by adenovirus?. J Med MicrobDiagn. 2015;4:180.
14. Djibril MA, et al. Profile of people living with hiv in intensive medical care in togo: epidemiological and evolutionary aspects. J Hematol Thrombo Dis. 2015;3:201.
15. Vita R. The much overlooked “materials and methods”. Immunome Res. 2015;5:e004.
16. McCullough KC, et al. Dendritic cell targets for self-replicating rna vaccines. J Blood Lymph. 2015;5:132.
17. Lee G. Cancerous immunoglobulins in cancer immunology. J Clin Cell Immunol. 2014;5:279.
18. Saida B, et al. Haplotypes of polymorphic antigen processing genes for low molecular mass polypeptides (lmp2 and lmp7) are strongly associated with type 1 diabetes in north india. J Diabetes Metab. 2014;5:451.
19. Cui Hua Liu. M. tuberculosis and macrophages: co-existence and co-evolution. J Pulm Respir Med; 2014;4:e133.
20. Lee G, et al. Potential roles of cancerous immunoglobulins in the immunology of cancer cells. J Clin Cell Immunol. 2014;5:200.
21. Chawla PC and Chawla A. The promise of oncoimmunology: integrating immunotherapy with conventional cancer treatments. J Integr Oncol. 2014;3:124.
22. Ohhashi T and Kawai Y. New lymphology combined with lymphatic physiology, innate immunology, and oncology. J Blood Lymph. 2014;4:126.
23. Yu X, et al. Successful treatment of severe psoriatic arthritis and psoriasis with double filtration plasmapheresis. J Clin Cell Immunol. 2014;5:222.
24. Pawlak-Adamska E, et al. Tagging snps in the excision repair cross-complementing group 4 (ercc4) gene increased risk of cervical squamous cell carcinoma (cscc) and modulate the disease outcome. J Carcinog Mutagen. 2014;5:172.
25. Shrestha BM. Immunology for renal transplantation: a review. J Transplant Technol Res. 2014;4:130.
26. Clark CS. Stress, Psychoneuroimmunology and self-care: what every nurse needs to know. J Nurs Care. 2014;3:146.
27. Thabet Y, et al. Systemic Lupus erythematosus in children: a study about 37 Tunisian cases. J Clin Cell Immunol. 2014;5:192.
28. Kwong KYC, et al. Variability in measurement of allergen skin testing results among allergy-immunology specialists. J Allergy Ther. 2014;5:160.
29. Yousef EM, et al. Deregulated expression of anxa1 in human high-grade breast cancers. J Mol Biomark Diagn. 2013;4:155.
30. Sakhno LV, et al. Low antigen-specific t-cell response in pulmonary tuberculosis is associated with impaired phenotype and functions of interferon-a induced dendritic cells. J Clin Cell Immunol. 2013;4:169.

e-ISSN: 2319-9865
p-ISSN: 2322-0104

31. Regasa B. Drug resistance patterns of bacterial pathogens from adult patients with pneumonia in arba minch hospital, south Ethiopia. J Med Microb Diagn. 2014;3:151.
32. Oninla OA, et al. Superficial fungi skin infections: the bane of dermatoses in Nigeria. J Med Microb Diagn. 2014;3:152.
33. Therese KL. A pilot study on the detection of multidrug resistant tuberculosis in hospital based population of chennai, India. J Med Microb Diagn. 2014;3:153.
34. Isaiah IN. Immunoinflammation and elevated serum procalcitonin in patients with resistant strain mycobacterium tuberculosis in Benin Metropolis. J Med Microb Diagn. 2014;3:154.
35. Isaiah IN and Ibhoje UU. Aflatoxin, G1, G2 and M1 prenatal exposure and its sero-dynamics amongst pregnant mothers in Adamawa state, North East of Nigeria. J Med Microb Diagn. 2014;3:155.
36. Jiang S. Immunity against fungal infections. Immunol Immunogenet Insights. 2016;8:3-6.
37. Huth TK, et al. Killer cell immunoglobulin-like receptor genotype and haplotype investigation of natural killer cells from an australian population of chronic fatigue syndrome/myalgic encephalomyelitis patients. Gene Regul Syst Bio 2016;10:43-49.
38. Choquet S. Classification and treatment of posttransplant lymphoproliferative disorders. Lymphoma and Chronic Lymphocytic Leukemias. 2016;6:13-19.
39. Chomlak RD, et al. Case Study: Giant cell arteritis with vertebral artery stenosis. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:103-107.
40. Fragkou P, et al. A case of organizing pneumonia (op) associated with pembrolizumab. Drug Target Insights. 2016;10:9-12.
41. Rayes H Al, et al. Apolipoprotein E gene polymorphisms in saudi patients with systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:81-87.
42. Gaudreau PO, et al. The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Cancer Biomark. 2016;2:15-33.
43. Tambunan USF, et al. Vaccine design for h5n1 based on b- and t-cell epitope predictions. Bioinformatics and Biology Insights. 2016;10:27-35.
44. Baroudi MEl. Immunomediated pan-cancer regulation networks are dominant fingerprints after treatment of cell lines with demethylation. Cancer Inform. 2016;15:45-64.
45. Reinwald M, et al. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights. 2015;3:55-68.
46. Packialakshmi B, et al. Proteomic changes in chicken plasma induced by salmonella typhimurium lipopolysaccharides. Proteomics Insights. 2016;7:1-9.
47. Bashiardes S, et al. Use of metatranscriptomics in microbiome research. Bioinform Biol Insights. 2016;10:19-25.
48. Teijido PG, et al. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol. 2016;1:31-39.
49. Elyamany G, et al. Hemophagocytic lymphohistiocytosis: single-center series of 12 cases from saudi arabia. Clin Med Insights Pediatr. 2016;10:21-26.

e-ISSN: 2319-9865
p-ISSN: 2322-0104

50. Yoshifuji H. Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;1:141-146.